DXCM News and Press, DexCom Inc. From 01/26/23

Initiating coverage on medical equipment makers for diabetes, Wolfe Research granted an Outperform rating for CGM device maker DexCom ( NASDAQ: DXCM ), and Peer Perform ratings for insulin pump makers Tandem Diabetes ( NASDAQ: TNDM ) and Insulet Corporation ( NASDAQ: PODD ...

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and full year 2022 financial results after market close on Thursday, February 9, 2023. Management will hold a conference call to review the company's fourth quarter and full year 2022 performance starting at ...

Summary The Top Six Healthcare Products and Service companies are some of the most popular investments in the market. However, they offer varying financial profiles. To understand where opportunity may lie, I ranked the group according to various financial metrics. Read on to se...

Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Large Cap Growth Strategy takes a concentrated,...

A discussion of "growth stocks" may not thrill investors quite the way it did just a year or two ago, but this type of investment is quite the horror show some make it out to be. Share prices are a bit more volatile across many sectors at the moment, but there are some great businesses still gene...

Dexcom G6 was the first Continuous Glucose Monitoring (CGM) System to be officially listed by the NIHB Drug Benefit program. Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (rtCGM), is pleased to announce that coverage for Dexcom G6 rtCGM Syst...

Summary Right now, Jay Powell's job is to suppress the money supply. The stock market is one of the greatest creators of wealth in our economy. It follows that as the rate-rising regime recedes, a roaring rally in stocks will resume. The potential could be as much as 20% in just a f...

The start of a new year may or may not signal the recovery of the broader stock market, but great businesses are staying largely above the fray even if share prices remain volatile. From healthcare to consumer goods, quality companies continuing to build upon a track record of growth that possess...

Last year, the Nasdaq Composite experienced a downturn due to a combination of negative economic and political factors. Even though some of these issues are still present, bear markets typically last less than a year. So there is a decent chance that equities will start a rally at some point ...

Glucose monitoring company DexCom ( NASDAQ: DXCM ) expects Q4 revenue to be at least $815M, an increase of 17% Y/Y on a reported basis and 20% on an organic basis. The Q4 revenue consensus stands at $808M. U.S. segment's revenue is expected to be ~$606M, up 17% ...